Indoco Remedies liquidity ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendLast 12Mto Sep 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
2.23×————
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
1.13×1.13×1.24×1.56×1.90×
0.75×0.75×0.72×0.98×1.14×
44.925.912.122.111.9
253141193342384
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

INDOCO₹231.00

Indoco Remedies Limited

· Pharma & Health
₹ CrorePeersSAIPARENTPANACEABIOHIKALWINDLASHESTERBIODCALSYNCOMFSOLARAMcap ₹2,132 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/09/2026
Altman Z-Score (Other Equity as RE)————2.23
Current Ratio1.901.561.241.131.13
Quick Ratio1.140.980.720.750.75
Cash, Equiv & ST Investments11.922.112.125.944.9
Working Capital383.7342.3193.4140.8253.4
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.